DK3126391T3 - ANTISTOFFER MOD HPA-1a - Google Patents
ANTISTOFFER MOD HPA-1a Download PDFInfo
- Publication number
- DK3126391T3 DK3126391T3 DK15713749T DK15713749T DK3126391T3 DK 3126391 T3 DK3126391 T3 DK 3126391T3 DK 15713749 T DK15713749 T DK 15713749T DK 15713749 T DK15713749 T DK 15713749T DK 3126391 T3 DK3126391 T3 DK 3126391T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibodies against
- against hpa
- hpa
- antibodies
- Prior art date
Links
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 title 1
- 102000057154 human ITGB3 Human genes 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1405775.6A GB201405775D0 (en) | 2014-03-31 | 2014-03-31 | Antibodies |
GBGB1417614.3A GB201417614D0 (en) | 2014-10-06 | 2014-10-06 | Antibodies |
PCT/EP2015/057102 WO2015150417A1 (en) | 2014-03-31 | 2015-03-31 | ANTIBODIES AGAINST HPA-1a |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3126391T3 true DK3126391T3 (da) | 2019-11-25 |
Family
ID=52785093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15713749T DK3126391T3 (da) | 2014-03-31 | 2015-03-31 | ANTISTOFFER MOD HPA-1a |
Country Status (21)
Country | Link |
---|---|
US (2) | US10882919B2 (da) |
EP (1) | EP3126391B1 (da) |
AU (1) | AU2015239606C1 (da) |
BR (1) | BR112016022508A2 (da) |
CA (1) | CA2943857C (da) |
CY (1) | CY1122728T1 (da) |
DK (1) | DK3126391T3 (da) |
ES (1) | ES2757596T3 (da) |
HR (1) | HRP20192097T1 (da) |
HU (1) | HUE047455T2 (da) |
IL (1) | IL247988B2 (da) |
LT (1) | LT3126391T (da) |
ME (1) | ME03655B (da) |
MX (1) | MX2016012620A (da) |
NZ (1) | NZ724772A (da) |
PL (1) | PL3126391T3 (da) |
PT (1) | PT3126391T (da) |
RS (1) | RS59704B1 (da) |
RU (1) | RU2688627C2 (da) |
SI (1) | SI3126391T1 (da) |
WO (1) | WO2015150417A1 (da) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022212930A1 (en) * | 2021-04-02 | 2022-10-06 | Rallybio Ipa, Llc | Method of administering anti-hpa-1a gamma globulin |
EP4363444A1 (en) * | 2021-07-01 | 2024-05-08 | Rallybio IPA, LLC | Administration of anti-hpa-1a antibodies |
IL309661A (en) * | 2021-07-01 | 2024-02-01 | Rallybio Ipa Llc | A method for administering an anti-HPA-1A monoclonal antibody |
AU2022381210A1 (en) * | 2021-11-08 | 2024-05-02 | Rallybio Ipa, Llc | ASSAYS FOR QUANTIFICATION OF ANTI-HPA-1a ANTIBODIES |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990010457A1 (en) | 1989-03-14 | 1990-09-20 | New York University | Method of treating hiv infections using immunotoxins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
GB9223390D0 (en) | 1992-11-07 | 1992-12-23 | Common Services Agency | Anti-hpa1 testing |
GB9505447D0 (en) | 1995-03-17 | 1995-05-03 | Common Services Agency | Competitive binding assay |
AU7809698A (en) * | 1997-06-05 | 1998-12-21 | Johns Hopkins University, The | Identification of human heavy chain antibody fragment directed against human platelet alloantigen 1a(hpa-1a) |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
US20030027207A1 (en) | 2000-02-29 | 2003-02-06 | Filpula David Ray | Anti-platelet binding proteins and polymer conjugates containing the same |
JP3312204B2 (ja) | 2000-10-17 | 2002-08-05 | 学校法人 慶應義塾 | 血小板減少症の診断用キット |
GB0315754D0 (en) | 2003-07-04 | 2003-08-13 | Univ Aberdeen | Pharmaceutical compositions |
WO2005075496A1 (en) | 2004-02-06 | 2005-08-18 | Canadian Blood Services | A method for the simultaneous determination of blood group and platelet antigen genotypes |
CA2590164A1 (en) | 2005-01-26 | 2006-08-03 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
EP2397498A3 (en) | 2005-07-18 | 2013-11-27 | Amgen, Inc | Human anti-B7RP1 neutralizing antibodies |
US20090317413A1 (en) | 2005-11-15 | 2009-12-24 | Cambridge Enterprise Limited | Detection of human platelet antigen (hpa) antibodies |
CA2636265C (en) * | 2006-01-03 | 2016-07-12 | Tto Nord As | Preparation useful for, and method for treatment of neonatal alloimmune thrombocytopenia (nait) |
ATE468351T1 (de) | 2006-02-07 | 2010-06-15 | Diagnostische Forsch Stiftung | Peptidaptamer zum neutralisieren der bindung von platelet-antigen-spezifischen antikörpern und diagnostische und therapeutische anwendungen, die dieses enthalten |
WO2007102383A1 (en) | 2006-02-28 | 2007-09-13 | Oncotherapy Science, Inc. | Methods for damaging cells using effector functions of anti-epha4 antibodies |
EP2006304A1 (en) | 2007-06-22 | 2008-12-24 | Stiftung Für Diagnostische Forschung | Anti-HPA-5b monoclonal antibody |
JP5602426B2 (ja) | 2007-05-25 | 2014-10-08 | 日本赤十字社 | 新規GPIIIa遺伝子 |
EP2025685B1 (en) | 2007-08-15 | 2013-06-19 | Canadian Blood Services | Monoclonal antibodies against BETA3 integrins |
ES2740051T3 (es) | 2008-12-31 | 2020-02-05 | Bharat Serums & Vaccines Ltd | Anticuerpos monoclonales anti-RHD |
CN101892314B (zh) | 2010-06-22 | 2012-04-18 | 天津市秀鹏生物技术开发有限公司 | 用于检测人血小板同种抗原基因的引物组及试剂盒 |
ES2657236T3 (es) | 2013-04-26 | 2018-03-02 | Davos Diagnostics Ag | Tipificaciones de aloantígenos plaquetarios y pruebas de anticuerpos plaquetarios |
-
2015
- 2015-03-31 PL PL15713749T patent/PL3126391T3/pl unknown
- 2015-03-31 ES ES15713749T patent/ES2757596T3/es active Active
- 2015-03-31 HU HUE15713749A patent/HUE047455T2/hu unknown
- 2015-03-31 WO PCT/EP2015/057102 patent/WO2015150417A1/en active Application Filing
- 2015-03-31 MX MX2016012620A patent/MX2016012620A/es active IP Right Grant
- 2015-03-31 DK DK15713749T patent/DK3126391T3/da active
- 2015-03-31 US US15/300,656 patent/US10882919B2/en active Active
- 2015-03-31 PT PT157137498T patent/PT3126391T/pt unknown
- 2015-03-31 BR BR112016022508A patent/BR112016022508A2/pt not_active Application Discontinuation
- 2015-03-31 LT LTEP15713749.8T patent/LT3126391T/lt unknown
- 2015-03-31 AU AU2015239606A patent/AU2015239606C1/en active Active
- 2015-03-31 EP EP15713749.8A patent/EP3126391B1/en active Active
- 2015-03-31 RU RU2016142718A patent/RU2688627C2/ru active
- 2015-03-31 ME MEP-2019-328A patent/ME03655B/me unknown
- 2015-03-31 SI SI201531002T patent/SI3126391T1/sl unknown
- 2015-03-31 RS RS20191490A patent/RS59704B1/sr unknown
- 2015-03-31 CA CA2943857A patent/CA2943857C/en active Active
- 2015-03-31 NZ NZ724772A patent/NZ724772A/en unknown
-
2016
- 2016-09-22 IL IL247988A patent/IL247988B2/en unknown
-
2019
- 2019-11-21 CY CY20191101228T patent/CY1122728T1/el unknown
- 2019-11-21 HR HRP20192097TT patent/HRP20192097T1/hr unknown
-
2020
- 2020-12-09 US US17/116,882 patent/US11725063B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2015239606A1 (en) | 2016-10-20 |
MX2016012620A (es) | 2017-04-06 |
CA2943857C (en) | 2023-07-11 |
PT3126391T (pt) | 2019-11-27 |
NZ724772A (en) | 2023-03-31 |
EP3126391A1 (en) | 2017-02-08 |
EP3126391B1 (en) | 2019-08-21 |
RU2016142718A (ru) | 2018-05-07 |
AU2015239606C1 (en) | 2020-08-27 |
ES2757596T3 (es) | 2020-04-29 |
WO2015150417A1 (en) | 2015-10-08 |
IL247988B1 (en) | 2024-03-01 |
SI3126391T1 (sl) | 2020-04-30 |
IL247988A0 (en) | 2016-11-30 |
PL3126391T3 (pl) | 2020-05-18 |
RS59704B1 (sr) | 2020-01-31 |
US11725063B2 (en) | 2023-08-15 |
CY1122728T1 (el) | 2021-03-12 |
CA2943857A1 (en) | 2015-10-08 |
ME03655B (me) | 2020-07-20 |
BR112016022508A2 (pt) | 2017-10-10 |
RU2688627C2 (ru) | 2019-05-22 |
HUE047455T2 (hu) | 2020-04-28 |
RU2016142718A3 (da) | 2018-10-18 |
AU2015239606B2 (en) | 2020-06-04 |
US20210189005A1 (en) | 2021-06-24 |
LT3126391T (lt) | 2020-02-10 |
US10882919B2 (en) | 2021-01-05 |
US20170121422A1 (en) | 2017-05-04 |
HRP20192097T1 (hr) | 2020-04-03 |
IL247988B2 (en) | 2024-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3134402T3 (da) | 4-amino-imidazoquinolinforbindelser | |
DK3183051T3 (da) | Væske-til-luftmembranenergivekslere | |
DK3211743T3 (da) | Ø-til-netværk-omskiftningsfremgangsmåde | |
DK3222714T3 (da) | Phytasemutanter | |
DK3119396T3 (da) | Muscarinreceptoragonister | |
DK3006072T3 (da) | Karadgang | |
DE112015001664A5 (de) | Betätigungsaktuator | |
DK3183340T3 (da) | Termolabile exonukleaser | |
DK3154703T3 (da) | Fuldkappe-snekkecentrifuge | |
DK3110439T3 (da) | Pcsk9-vacciner | |
FI20145040A (fi) | Ajoneuvon rengas | |
DE112015005041A5 (de) | Gargerätevorrichtung | |
DK3126391T3 (da) | ANTISTOFFER MOD HPA-1a | |
DE102014000623A8 (de) | Halbhohlnietelement | |
DK3009858T3 (da) | Skyradar | |
DE112015001633A5 (de) | Betätigungsaktuator | |
DK3447493T3 (da) | Proteinrettede ortologer | |
ES1133830Y (es) | Columbario | |
DK3091875T3 (da) | Vipbar taburet | |
DE202014005655U8 (de) | llluminationsvorrichtung | |
DE112015005055A5 (de) | Gargerätevorrichtung | |
DK3191825T3 (da) | Kreatininbiosensor | |
FI10894U1 (fi) | Putkieristyskouru | |
ES1137381Y (es) | Trompo | |
ES1136185Y (es) | Huevera |